Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States
The information in the brief version is excerpted directly from the full-text guidelines. The brief version is a compilation of the tables and boxed recommendations.
Last Updated: December 7, 2018; Last Reviewed: December 7, 2018
|Formulation||Dosing Recommendations||Use in Pregnancy|
Note: As of October 2017, Vitekta (i.e., EVG as a single-entity formulation) is no longer available
||Standard Adult Dose (Genvoya and Stribild):
||Evidence of high placental transfer of EVG and low transfer of COBI.b
Insufficient data to assess for teratogenicity in humans. No evidence of teratogenicity in rats or rabbits.
EVG/COBI is not recommended for initial use in pregnancy. For women who become pregnant while taking EVG/COBI, consider switching to a more effective, recommended regimen. If an EVG/COBI regimen is continued, doses should not be administered within 2 hours of ingestion of any preparation containing minerals such as iron or calcium, including prenatal vitamins.
a Individual ARV drug dosages may need to be adjusted in patients with renal or hepatic insufficiency (for details, see the Adult and Adolescent Guidelines Appendix B, Table 8).
b Placental transfer categories—Mean or median cord blood/maternal delivery plasma drug ratio:
Key to Acronyms: COBI = cobicistat; EFV = efavirenz; EVG = elvitegravir; EVG/c = elvitegravir/cobicistat; FDC= fixed-dose combination; FTC = emtricitabine PK = pharmacokinetic; TAF = tenofovir alafenamide; TDF = tenofovir disoproxil fumarate; TDM = therapeutic drug monitoring; WHO = World Health Organization
- AIDSinfo Drug Database
- AIDSinfo Patient Materials: Preventing Mother-to-Child Transmission of HIV
- AIDSinfo Patient Materials: HIV Medicines During Pregnancy and Childbirth
- AIDSinfo Patient Materials: Protecting Baby from HIV
- AETC National HIV Curriculum
- How to Cite These Guidelines
- Perinatal Guidelines Archive